Inositol 12 g per day was added to ongoing anti-Parkinson therapy in a controlled randomized cross-over design in nine patients. No therapeutic eect was found.
Plasma inositol is not elevated in Alzheimer's disease
β Scribed by Hannah Kastel; Hady Shimon; Galila Agam
- Publisher
- John Wiley and Sons
- Year
- 1998
- Tongue
- English
- Weight
- 77 KB
- Volume
- 13
- Category
- Article
- ISSN
- 0885-6222
No coin nor oath required. For personal study only.
β¦ Synopsis
Brain inositol levels have been previously reported as elevated in Alzheimer's disease (AD) in brain. Brain inositol levels may be reΒ―ected in plasma levels. We therefore studied plasma inositol levels in 20 AD patients and 20 controls. Plasma inositol levels in the AD patients did not dier from values found in the controls.
π SIMILAR VOLUMES
## Abstract Alzheimer's disease (AD) is characterized by progressive loss of memory and cognition. Our laboratory and many others have shown that the AD brain is under extensive oxidative stress. Numerous therapeutic approaches to AD therapy have been hypothesized. Among these are exogenous antioxi
## Objectives: It has been suggested that oxidative injuries have an important role in the pathogenesis of alzheimer's disease (ad). in this study, we assess whether the plasma levels of albumin, bilirubin, and uric acid would be altered in the ad patients compared to those of the healthy controls.
## Abstract Various factors have been suggested to participate in Alzheimer's disease (AD) pathology, and some inflammatory cytokines may play an important role in the development of AD. InterferonβΞ³ (__IFNG__), an important proβinflammatory cytokine, is encoded by a single gene mapped to chromosom
## Background: The association between the mutant allele of mitochondrial aldehyde dehydrogenase (aldh2\*2) and alzheimer's disease (ad) has been controversial and only so far investigated in cross-sectional studies. this study aimed to investigate the longitudinal association between aldh2\*2 and